Forest Laboratories, Inc. Announces Settlement of BYSTOLIC® Patent Litigation
NEW YORK–November 7, 2013–(BUSINESS WIRE)–Forest Laboratories, Inc. (NYSE:FRX) and Forest Laboratories Holdings, Ltd. (collectively, “Forest”) announced today that they have entered into a settlement...
View ArticleForest Laboratories Names A. Robert D. Bailey Senior Vice President, Chief...
NEW YORK–November 11, 2013–(BUSINESS WIRE)–Forest Laboratories, Inc. (NYSE:FRX) today announced that Robert Bailey was appointed Senior Vice President, Chief Legal Officer General Counsel. In this...
View ArticleForest Laboratories and Gedeon Richter Receive Complete Response Letter for...
NEW YORK & BUDAPEST, Hungary– November 21, 2013 — (BUSINESS WIRE)–Forest Laboratories, Inc. (NYSE:FRX) and Gedeon Richter Plc. announced that the U.S. Food and Drug Administration (FDA) issued a...
View ArticleForest to Acquire U.S. Marketing Rights to Saphris® (asenapine) from Merck
Forest acquires exclusive rights to Saphris® in the United States for the treatment of schizophrenia and acute bipolar mania in adults for $240 million plus sales-based milestones and on-going supply...
View ArticleForest Laboratories Announces Appointments to its Executive Team
NEW YORK– December 9, 2013 — (BUSINESS WIRE) –Forest Laboratories, Inc. (NYSE:FRX) today announced appointments to its executive leadership team. The appointments are part of Forest’s announced plans...
View ArticleForest Announces New FETZIMA™ (levomilnacipran ER capsules) Now Available in...
NEW YORK– December 19, 2013 — (BUSINESS WIRE)–Forest Laboratories, Inc. (NYSE:FRX) announced today that FETZIMA™ (levomilnacipran ER capsules), is now available in pharmacies throughout the United...
View ArticleActavis Completes Forest Laboratories Acquisition
Creates an Innovative New Model in Specialty Pharmaceuticals Leadership – – $15.0 Billion Anticipated Pro Forma Combined Revenue – – Establishes Blockbuster Franchises in CNS, Gastroenterology, Women’s...
View Article
More Pages to Explore .....